112 related articles for article (PubMed ID: 19695765)
1. A validation study of new risk grouping criteria for postoperative treatment in stage IB cervical cancers without high-risk factors: rethinking the Gynecologic Oncology Group criteria.
Chang SJ; Kim WY; Yoo SC; Yoon JH; Chun M; Chang KH; Ryu HS
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):91-6. PubMed ID: 19695765
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant small field pelvic radiation for patients with high risk, stage IB lymph node negative cervix carcinoma after radical hysterectomy and pelvic lymph node dissection. A pilot study.
Kridelka FJ; Berg DO; Neuman M; Edwards LS; Robertson G; Grant PT; Hacker NF
Cancer; 1999 Nov; 86(10):2059-65. PubMed ID: 10570432
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy.
Liu MT; Hsu JC; Liu WS; Wang AY; Huang WT; Chang TH; Pi CP; Huang CY; Huang CC; Chou PH; Chen TH
Eur J Cancer Care (Engl); 2008 Mar; 17(2):174-81. PubMed ID: 18302655
[TBL] [Abstract][Full Text] [Related]
4. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer.
Havrilesky LJ; Leath CA; Huh W; Calingaert B; Bentley RC; Soper JT; Alvarez Secord A
Gynecol Oncol; 2004 May; 93(2):429-34. PubMed ID: 15099957
[TBL] [Abstract][Full Text] [Related]
5. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy.
Tsai CS; Lai CH; Wang CC; Chang JT; Chang TC; Tseng CJ; Hong JH
Gynecol Oncol; 1999 Dec; 75(3):328-33. PubMed ID: 10600284
[TBL] [Abstract][Full Text] [Related]
6. Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy.
Yessaian A; Magistris A; Burger RA; Monk BJ
Gynecol Oncol; 2004 Jul; 94(1):61-6. PubMed ID: 15262120
[TBL] [Abstract][Full Text] [Related]
7. Cervical cancer: combined modality therapy.
Grigsby PW
Cancer J; 2001; 7 Suppl 1():S47-50. PubMed ID: 11504285
[TBL] [Abstract][Full Text] [Related]
8. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation.
Aoki Y; Sasaki M; Watanabe M; Sato T; Tsuneki I; Aida H; Tanaka K
Gynecol Oncol; 2000 May; 77(2):305-9. PubMed ID: 10785483
[TBL] [Abstract][Full Text] [Related]
9. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma.
Monk BJ; Cha DS; Walker JL; Burger RA; Ramsinghani NS; Manetta A; DiSaia PJ; Berman ML
Gynecol Oncol; 1994 Jul; 54(1):4-9. PubMed ID: 8020837
[TBL] [Abstract][Full Text] [Related]
10. Early stage cervical cancer: adjuvant treatment in negative lymph node cases.
Sartori E; Tisi G; Chiudinelli F; La Face B; Franzini R; Pecorelli S
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S170-4. PubMed ID: 17765298
[TBL] [Abstract][Full Text] [Related]
11. Stromal invasion of the cervix can be excluded from the criteria for using adjuvant radiotherapy following radical surgery for patients with cervical cancer.
Shimada M; Kigawa J; Takahashi M; Minagawa Y; Okada M; Kanamori Y; Itamochi H; Oishi T; Iba T; Terakawa N
Gynecol Oncol; 2004 Jun; 93(3):628-31. PubMed ID: 15196855
[TBL] [Abstract][Full Text] [Related]
12. Risk grouping in stage IB squamous cell cervical carcinoma.
Van de Putte G; Lie AK; Vach W; Baekelandt M; Kristensen GB
Gynecol Oncol; 2005 Oct; 99(1):106-12. PubMed ID: 16137752
[TBL] [Abstract][Full Text] [Related]
13. Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors.
Uno T; Ito H; Itami J; Yasuda S; Isobe K; Hara R; Sato T; Minoura S; Shigematsu N; Kubo A
Anticancer Res; 2000; 20(3B):2235-9. PubMed ID: 10928184
[TBL] [Abstract][Full Text] [Related]
14. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?
Kamelle SA; Rutledge TL; Tillmanns TD; Gould NS; Cohn DE; Wright J; Herzog TJ; Rader JS; Gold MA; Johnson GA; Walker JL; Mannel RS; McMeekin DS
Gynecol Oncol; 2004 Aug; 94(2):249-55. PubMed ID: 15297159
[TBL] [Abstract][Full Text] [Related]
15. Isolated full-thickness cervical stromal invasion warrants post-hysterectomy pelvic radiotherapy in FIGO stages IB-IIA uterine cervical carcinoma.
Moon SH; Wu HG; Ha SW; Lee HP; Kang SB; Song YS; Park NH; Kim JW; Park IA; Kim BH
Gynecol Oncol; 2007 Jan; 104(1):152-7. PubMed ID: 16935323
[TBL] [Abstract][Full Text] [Related]
16. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors.
Mabuchi S; Morishige K; Isohashi F; Yoshioka Y; Takeda T; Yamamoto T; Yoshino K; Enomoto T; Inoue T; Kimura T
Gynecol Oncol; 2009 Dec; 115(3):482-7. PubMed ID: 19783286
[TBL] [Abstract][Full Text] [Related]
17. Post-hysterectomy radiotherapy in FIGO stage IB-IIB uterine cervical carcinoma.
Kim JH; Kim HJ; Hong S; Wu HG; Ha SW
Gynecol Oncol; 2005 Feb; 96(2):407-14. PubMed ID: 15661229
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy after primary surgery for stage I-IIA carcinoma of the cervix.
Thomas GM
J Natl Cancer Inst Monogr; 1996; (21):77-83. PubMed ID: 9023833
[TBL] [Abstract][Full Text] [Related]
19. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
[TBL] [Abstract][Full Text] [Related]
20. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?
Rutledge TL; Kamelle SA; Tillmanns TD; Gould NS; Wright JD; Cohn DE; Herzog TJ; Rader JS; Gold MA; Johnson GA; Walker JL; Mannel RS; McMeekin DS
Gynecol Oncol; 2004 Oct; 95(1):70-6. PubMed ID: 15385112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
